Benepali etanercept less immunogenic than reference product in Phase III

A research letter published in the British Journal of Dermatology reported that Benepali etanercept (SB4), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), was less immunogenic than its reference product

Read the full 313 word article

User Sign In